Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Notice of Results

Cyprotex PLC ("Cyprotex" or the "Company")

Notice of Results

15 March 2013 - Cyprotex PLC (AIM:CRX), the specialist preclinical contract research organisation (CRO) will announce its final results for the year ended 31 December 2012 on 21 March 2013.

For further information:

Cyprotex PLC
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Office
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
ir@cyprotex.com
www.cyprotex.com

N+1 Singer (Nomad and broker to Cyprotex)
Tel: +44 (0)20 7496 3000
Shaun Dobson
shaun.dobson@n1singer.com
Jenny Wyllie
jenny.wyllie@n1singer.com
www.nplus1singer.com

FTI Consulting
Simon Conway
Mo Noonan
Tel: +44 (0) 20 7831 3113
cyprotex@fticonsulting.com
www.fticonsulting.com

Notes to Editors

About Cyprotex PLC
Cyprotex is based in Macclesfield, near Manchester in the UK, and Watertown, MA in the US and is listed on the AIM market of the London Stock Exchange (CRX). The company was established in 1999 and works with more than 700 partners ranging from small biotechs to large pharma companies. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company’s core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services and predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction. For more information, see www.cyprotex.com.

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close